SynopsisSomatuline is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Somatuline market size is expected to reach US$ 1506.5 million by 2029, growing at a CAGR of 1.1% fro.....
SynopsisOctreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. The global Sandostatin LAR Dru.....
SynopsisPasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Pasireotide Drugs market size is expected to reach US$ 125 million by 20.....
SynopsisSignifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Signifor Drugs market size is expected to reach US$ 125 million by 2029, gr.....
SynopsisLanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Lanreotide Drugs market size is expected to reach US$ 1506.5 million by 2029, growing at a CAGR.....
SynopsisSomatuline is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Somatuline Drugs market size is expected to reach US$ 1506.5 million by 2029, growing at a CAGR of 1......
SynopsisPegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. The global Pegvisomant market size is expected to reach US$ 331.5 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is ma.....
SynopsisPegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. The global Somavert market size is expected to reach US$ 331.5 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is mainl.....
SynopsisPegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. The global Pegvisomant Drugs market size is expected to reach US$ 331.5 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market.....
SynopsisPegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. The global Somavert Drugs market size is expected to reach US$ 331.5 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is.....
